Several listed companies respond to the "miracle cure" incident, with products urgently taken off the shelves.

The "universal miracle drug" exosomes exposed by CCTV 3.15 Gala are reported to have illegally added ingredients. In response, Jinbo Biotechnology has released a statement calling for regulatory authorities to investigate. It was noted that multiple listed companies are involved in the exosome field. New Oxygen said that the related project has been taken down; Kanneng Health's subsidiary, Laisen, includes exosome therapy in its original business; Dongfulong has introduced exosome industrialization solutions. A search on the China Clinical Trial Registry for "exosomes" revealed that there are currently around 300 ongoing clinical trials, with over 70 clinical studies registered in the past year covering a wide range of diseases for intervention, such as sensitive skin diseases, arthritis, pneumonia, rhinitis, hair loss, dry eye syndrome, and facial rejuvenation.